The BTN1A1 Knockout KYSE-30 Polyclonal Cells consist of a heterogeneous pool of CRISPR/Cas9-edited polyclonal knockout cells derived from the human esophageal squamous cell carcinoma line KYSE-30. Through CRISPR/Cas9-mediated target-gene disruption, this product eliminates functional expression of butyrophilin subfamily 1 member A1 (BTN1A1), enabling loss-of-function studies without selection for individual clonal isolates. The polyclonal format preserves genetic diversity within the edited population, making it suitable for experiments that require biological replicates with minimized single-clone artifacts.
The host KYSE-30 cell line is a well-differentiated human esophageal squamous cell carcinoma line established from a primary tumor resected from a 64-year-old male patient. KYSE-30 cells serve as a widely accepted in vitro model for investigating the molecular mechanisms underlying esophageal squamous cell carcinoma pathogenesis, tumor progression, and therapeutic responsiveness. Their well-characterized background facilitates integration with existing data sets and comparative studies in esophageal cancer research.
The butyrophilin subfamily 1 member A1 (BTN1A1) gene encodes a transmembrane glycoprotein that functions in mammary gland lipid secretion and immunomodulation. BTN1A1??s role in lipid droplet trafficking is executed through direct interactions with xanthine oxidoreductase (XDH) and perilipin-2 (PLIN2), which are critical for the formation and secretion of milk fat globules. In immune contexts, BTN1A1 engagement modulates T cell receptor signaling as part of the butyrophilin-mediated immune checkpoint network, with expression regulated by prolactin, glucocorticoids, STAT5, and inflammatory cytokines. The protein also influences downstream effectors involved in lipid droplet secretion and T cell activity, highlighting its dual functionality in metabolic and immune pathways.
In the KYSE-30 esophageal squamous cell carcinoma background, BTN1A1 knockout provides a targeted platform to dissect potential contributions of butyrophilin-mediated lipid trafficking and immune evasion to cancer cell behavior. Although BTN1A1 is predominantly studied in lactating mammary tissue, its expression in extramammary tissues and structural homology to immune checkpoint molecules suggest possible roles in tumor?immune interactions. Disruption of BTN1A1 may uncover context?dependent functions in lipid droplet dynamics and immune regulatory processes relevant to esophageal squamous cell carcinoma growth and metastasis.
Researchers can employ these polyclonal knockout cells in a wide range of investigative workflows, including Western blotting and RT-qPCR to confirm BTN1A1 ablation, BODIPY?based lipid droplet staining to assess alterations in lipid storage, and co-immunoprecipitation or immunofluorescence to probe protein interactions. Functional assays such as RNA sequencing and flow cytometry enable transcriptomic profiling and immune marker analysis, while migration, invasion, and apoptosis assays facilitate cancer biology studies. Drug target validation and immune checkpoint modulation experiments are also feasible, making this product suitable for translational research in esophageal squamous cell carcinoma. For additional information, please contact Ascent Research.
